open access

Vol 5, No 5 (2009)
Case report
Published online: 2009-12-01
Get Citation

Complete remission in metastatic HER2-posistive breast cancer patient after lapatinib with capecitabine treatment - a case report

Anna Czerepińska, Elżbieta Starosławska, Anna Twardosz
Onkol. Prak. Klin 2009;5(5):211-214.

open access

Vol 5, No 5 (2009)
CASE REPORTS
Published online: 2009-12-01

Abstract

Lapatinib in combination with capecitabine is an effective treatment modality in metastatic HER2-posistive breast cancer patients progressing after the treatment with anthracyclines, taxanes and trastuzumab. However, the complete remissions are incidental. In this case report we present the patient who achieved durable complete remission after 7 months of lapatinib in combination with capecitabine treatment.

Abstract

Lapatinib in combination with capecitabine is an effective treatment modality in metastatic HER2-posistive breast cancer patients progressing after the treatment with anthracyclines, taxanes and trastuzumab. However, the complete remissions are incidental. In this case report we present the patient who achieved durable complete remission after 7 months of lapatinib in combination with capecitabine treatment.
Get Citation

Keywords

metastatic breast cancer; HER2/neu; lapatinib with capecitabine

About this article
Title

Complete remission in metastatic HER2-posistive breast cancer patient after lapatinib with capecitabine treatment - a case report

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 5 (2009)

Article type

Case report

Pages

211-214

Published online

2009-12-01

Bibliographic record

Onkol. Prak. Klin 2009;5(5):211-214.

Keywords

metastatic breast cancer
HER2/neu
lapatinib with capecitabine

Authors

Anna Czerepińska
Elżbieta Starosławska
Anna Twardosz

References (18)
  1. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785): 177–182.
  2. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001; 344(11): 783–792.
  3. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005; 23(19): 4265–4274.
  4. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006; 24(18): 2786–2792.
  5. Gasparini G, Gion M, Mariani L, et al. Randomized Phase II Trial of weekly paclitaxel alone versus trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat. 2007; 101(3): 355–365.
  6. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007; 110(5): 965–972.
  7. Montemurro F, Donadio M, Clavarezza M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006; 11(4): 318–324.
  8. Montemurro F, Redana S, Viale G, et al. Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era. Clin Breast Cancer. 2008; 8(5): 436–442.
  9. Konecny GE, Pegram MD, Venkatesan N, et al. Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res. 2006; 66(3): 1630–1639.
  10. Spector NL, Xia W, Burris H, et al. Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies. J Clin Oncol. 2005; 23(11): 2502–2512.
  11. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355(26): 2733–2743.
  12. Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008; 112(3): 533–543.
  13. Pietras RJ, Fendly BM, Chazin VR, et al. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells. Oncogene. 1994; 9(7): 1829–1838.
  14. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene. 1999; 18(13): 2241–2251.
  15. Pietras RJ, Pegram MD, Finn RS, et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. Oncogene. 1998; 17(17): 2235–2249.
  16. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998; 16(8): 2659–2671.
  17. Sarti M, Pagani O, Bertoni F, et al. Retinal metastases treated with lapatinib (L) in a young HER2-positive breast cancer patient: Case report. Journal of Clinical Oncology. 2008; 26(15_suppl): 12008.
  18. Starosławska E, Czerepińska A, Jankowski T, et al. Doświadczenia własne COZL w leczeniu miejscowo zaawansowanego i przerzutowego raka piersi z zastosowaniem schematu lapatynib z kapecytabiną po niepowodzeniu terapii z zastosowaniem trastuzumabu. Nowotwory. 2009; 9(supl. 1): 39–40.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl